Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience

被引:93
|
作者
Sanchorawala, Vaishali [1 ,2 ]
Sun, Fangui [2 ,3 ]
Quillen, Karen [2 ]
Sloan, J. Mark [1 ,2 ]
Berk, John L. [2 ]
Seldin, David C. [1 ,2 ]
机构
[1] Boston Univ, Sch Med, Hematol Oncol Sect, Boston, MA 02215 USA
[2] Boston Univ, Sch Med, Amyloidosis Ctr, Boston, MA 02215 USA
[3] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA
关键词
LIGHT-CHAIN AMYLOIDOSIS;
D O I
10.1182/blood-2015-08-662726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:2345 / 2347
页数:5
相关论文
共 50 条
  • [1] Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation
    Gupta, Aarti
    Kumar, Lalit
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (01) : 49 - 52
  • [2] Long-Term Outcome of Patients with AL Amyloidosis Treated with High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience at a Single Center
    Sanchorawala, Vaishali
    Doros, Gheorghe
    Quillen, Karen
    Sloan, J. Mark
    Shelton, Anthony C.
    Brauneis, Dina
    Finn, Kathleen T.
    Seldin, David C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S47 - S48
  • [3] Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center
    Sanchorawala, Vaishali
    Doros, Gheorghe
    Quillen, Karen
    Sloan, John Mark
    Shelton, Anthony C.
    Brauneis, Dina
    Finn, Kathleen T.
    Seldin, David C.
    BLOOD, 2013, 122 (21)
  • [4] Long-term outcome-of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
    Sanchorawala, Vaishali
    Skinner, Martha
    Quillen, Karen
    Finn, Kathleen T.
    Doros, Gheorghe
    Seldin, David C.
    BLOOD, 2007, 110 (10) : 3561 - 3563
  • [5] Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis
    J B Perz
    A Rahemtulla
    C Giles
    R M Szydlo
    J Davis
    D Gopaul
    J Gillmore
    C J Mathias
    P N Hawkins
    J F Apperley
    Bone Marrow Transplantation, 2006, 37 : 937 - 943
  • [6] Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis
    Perz, JB
    Rahemtulla, A
    Giles, C
    Szydlo, RM
    Davis, J
    Gopaul, D
    Gillmore, J
    Mathias, CJ
    Hawkins, PN
    Apperley, JF
    BONE MARROW TRANSPLANTATION, 2006, 37 (10) : 937 - 943
  • [7] LONG-TERM RESULTS OF 174 PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS TREATED WITH HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
    Hegenbart, U.
    Bochtler, T.
    Dreger, P.
    Kimmich, C.
    Ziehl, R.
    Goldschmidt, H.
    Ho, A.
    Schoenland, S.
    HAEMATOLOGICA, 2014, 99 : 504 - 504
  • [8] Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
    Teresa Cibeira, Maria
    Sanchorawala, Vaishali
    Seldin, David C.
    Quillen, Karen
    Berk, John L.
    Dember, Laura M.
    Segal, Adam
    Ruberg, Frederick
    Meier-Ewert, Hans
    Andrea, Nancy T.
    Sloan, J. Mark
    Finn, Kathleen T.
    Doros, Gheorghe
    Blade, Joan
    Skinner, Martha
    BLOOD, 2011, 118 (16) : 4346 - 4352
  • [9] Relapse rate and long-term survival of AL amyloidosis patients treated with high-dose melphalan and autologous stem cell transplantation (HDM/SCT).
    Seldin, David C.
    Skinner, Martha
    Oran, Betul
    Quillen, Karen
    Finn, Kathleen T.
    Sanchorawala, Vaishali
    BLOOD, 2006, 108 (11) : 882A - 882A
  • [10] Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994–2009
    S Rosengren
    U-H Mellqvist
    H Nahi
    K Forsberg
    S Lenhoff
    O Strömberg
    L Ahlberg
    O Linder
    K Carlson
    Bone Marrow Transplantation, 2016, 51 : 1569 - 1572